Cargando…

Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort

Reduced risk of HIV-1 infection correlated with antibody responses to the envelope variable 1 and 2 regions in the RV144 vaccine trial. To understand the relationship between antibody responses, V2 sequence, and structure, plasma samples (n = 16) from an early acute HIV-1 infection cohort from Thail...

Descripción completa

Detalles Bibliográficos
Autores principales: Trinh, Hung V., Gohain, Neelakshi, Pham, Peter T., Hamlin, Christopher, Song, Hongshuo, Sanders-Buell, Eric, Bose, Meera, Eller, Leigh A., Tovanabutra, Sodsai, Michael, Nelson L., Robb, Merlin L., Joyce, M. Gordon, Rao, Mangala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523213/
https://www.ncbi.nlm.nih.gov/pubmed/31010245
http://dx.doi.org/10.3390/cells8040365
_version_ 1783419282275696640
author Trinh, Hung V.
Gohain, Neelakshi
Pham, Peter T.
Hamlin, Christopher
Song, Hongshuo
Sanders-Buell, Eric
Bose, Meera
Eller, Leigh A.
Tovanabutra, Sodsai
Michael, Nelson L.
Robb, Merlin L.
Joyce, M. Gordon
Rao, Mangala
author_facet Trinh, Hung V.
Gohain, Neelakshi
Pham, Peter T.
Hamlin, Christopher
Song, Hongshuo
Sanders-Buell, Eric
Bose, Meera
Eller, Leigh A.
Tovanabutra, Sodsai
Michael, Nelson L.
Robb, Merlin L.
Joyce, M. Gordon
Rao, Mangala
author_sort Trinh, Hung V.
collection PubMed
description Reduced risk of HIV-1 infection correlated with antibody responses to the envelope variable 1 and 2 regions in the RV144 vaccine trial. To understand the relationship between antibody responses, V2 sequence, and structure, plasma samples (n = 16) from an early acute HIV-1 infection cohort from Thailand infected with CRF01_AE strain were analyzed for binding to V2 peptides by surface plasmon resonance. Five participants with a range of V2 binding responses at week 24 post-infection were further analyzed against a set of four overlapping V2 peptides that were designed based on envelope single-genome amplification. Antibody responses that were relatively consistent over the four segments of the V2 region or a focused response to the C-strand (residues 165–186) of the V2 region were observed. Viral escape in the V2 region resulted in significantly reduced antibody binding. Structural modeling indicated that the C-strand and the sites of viral variation were highly accessible in the open conformation of the HIV-1 Env trimer. V2 residues, 165–186 are preferentially targeted during acute infection. Residues 169–184 were also preferentially targeted by the protective immune response in the RV144 trial, thus emphasizing the importance of these residues for vaccine design.
format Online
Article
Text
id pubmed-6523213
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65232132019-06-03 Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort Trinh, Hung V. Gohain, Neelakshi Pham, Peter T. Hamlin, Christopher Song, Hongshuo Sanders-Buell, Eric Bose, Meera Eller, Leigh A. Tovanabutra, Sodsai Michael, Nelson L. Robb, Merlin L. Joyce, M. Gordon Rao, Mangala Cells Article Reduced risk of HIV-1 infection correlated with antibody responses to the envelope variable 1 and 2 regions in the RV144 vaccine trial. To understand the relationship between antibody responses, V2 sequence, and structure, plasma samples (n = 16) from an early acute HIV-1 infection cohort from Thailand infected with CRF01_AE strain were analyzed for binding to V2 peptides by surface plasmon resonance. Five participants with a range of V2 binding responses at week 24 post-infection were further analyzed against a set of four overlapping V2 peptides that were designed based on envelope single-genome amplification. Antibody responses that were relatively consistent over the four segments of the V2 region or a focused response to the C-strand (residues 165–186) of the V2 region were observed. Viral escape in the V2 region resulted in significantly reduced antibody binding. Structural modeling indicated that the C-strand and the sites of viral variation were highly accessible in the open conformation of the HIV-1 Env trimer. V2 residues, 165–186 are preferentially targeted during acute infection. Residues 169–184 were also preferentially targeted by the protective immune response in the RV144 trial, thus emphasizing the importance of these residues for vaccine design. MDPI 2019-04-19 /pmc/articles/PMC6523213/ /pubmed/31010245 http://dx.doi.org/10.3390/cells8040365 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Trinh, Hung V.
Gohain, Neelakshi
Pham, Peter T.
Hamlin, Christopher
Song, Hongshuo
Sanders-Buell, Eric
Bose, Meera
Eller, Leigh A.
Tovanabutra, Sodsai
Michael, Nelson L.
Robb, Merlin L.
Joyce, M. Gordon
Rao, Mangala
Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort
title Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort
title_full Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort
title_fullStr Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort
title_full_unstemmed Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort
title_short Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort
title_sort humoral response to the hiv-1 envelope v2 region in a thai early acute infection cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523213/
https://www.ncbi.nlm.nih.gov/pubmed/31010245
http://dx.doi.org/10.3390/cells8040365
work_keys_str_mv AT trinhhungv humoralresponsetothehiv1envelopev2regioninathaiearlyacuteinfectioncohort
AT gohainneelakshi humoralresponsetothehiv1envelopev2regioninathaiearlyacuteinfectioncohort
AT phampetert humoralresponsetothehiv1envelopev2regioninathaiearlyacuteinfectioncohort
AT hamlinchristopher humoralresponsetothehiv1envelopev2regioninathaiearlyacuteinfectioncohort
AT songhongshuo humoralresponsetothehiv1envelopev2regioninathaiearlyacuteinfectioncohort
AT sandersbuelleric humoralresponsetothehiv1envelopev2regioninathaiearlyacuteinfectioncohort
AT bosemeera humoralresponsetothehiv1envelopev2regioninathaiearlyacuteinfectioncohort
AT ellerleigha humoralresponsetothehiv1envelopev2regioninathaiearlyacuteinfectioncohort
AT tovanabutrasodsai humoralresponsetothehiv1envelopev2regioninathaiearlyacuteinfectioncohort
AT michaelnelsonl humoralresponsetothehiv1envelopev2regioninathaiearlyacuteinfectioncohort
AT robbmerlinl humoralresponsetothehiv1envelopev2regioninathaiearlyacuteinfectioncohort
AT joycemgordon humoralresponsetothehiv1envelopev2regioninathaiearlyacuteinfectioncohort
AT raomangala humoralresponsetothehiv1envelopev2regioninathaiearlyacuteinfectioncohort